More legal trouble for KV Pharma; FDA sees uptick in Senate-approved funding;

> Investors have filed a class-action lawsuit against KV Pharma ($KV.A) for "false and/or misleading statements" the company made about the FDA granting it exclusive distribution rights for Makena, a drug for preventing premature births. Release

> The U.S. Senate yesterday approved funding of $2.5 billion for the FDA, up from $2.45 billion last year. It earmarked some of the funding for the recently passed Food Safety Modernization Act. Item

> Police have seized $30 million in counterfeit drugs in central China's Henan province. Story

> Contract manufacturer CMC Biologics will work with Daiichi Sankyo to develop and produce antibodies. Release

> Service provider Norwich Pharmaceuticals has boosted pilot production capabilities through a facility expansion that doubles its capacity. Announcement

> Lebanese security forces have shut down a counterfeit drug operation in Beirut, seizing 200 boxes of expired medicine and chemicals used in drug production. News

> High-potency API maker Carbogen Amcis has allied with liposomal formulations specialist Polymun Scientific. Story

> Service provider Norwich Pharmaceuticals has boosted pilot production capabilities through a facility expansion that doubles current capacity. Announcement

> High-potency API maker Carbogen Amcis has allied with liposomal formulations specialist Polymun Scientific. Story

> New on the FDA's drug shortages list: muscle-relaxant Pancuronium Bromide injection, 1 milligram/milliliter, 10-milliliter vial, due to a manufacturing delay at Hospira. Listing

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.